Biologics Contract Development & Manufacturing Organization Market revenue to hit USD 39 Billion by 2036, says Research Nester
08 févr. 2024 05h30 HE
|
Research Nester
New York, Feb. 08, 2024 (GLOBE NEWSWIRE) -- The global biologics contract development & manufacturing organization (CDMO) market size is projected to grow at a CAGR of over ~12% from 2024 to...
Labcorp Elevates Employee Health Benefits with WeightWatchers for Business Full-Spectrum Weight Health Platform
07 févr. 2024 09h05 HE
|
WW International Inc.
NEW YORK and BURLINGTON, N.C., Feb. 07, 2024 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW), (“WeightWatchers,” “WW,” or the “Company”) today announced that Labcorp (NYSE: LH), a global leader of...
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
31 janv. 2024 04h00 HE
|
AKAMPION
New clinical trial site opened in Italy for pectus excavatum and planned in Germany for bone reconstructionCompany aims to expand EU market authorization from custom-made to off-the-shelf products and...
YPrime's Latest Research Reveals Significant Impact of eCOA Platform Delays on Clinical Trial Efficiency
30 janv. 2024 08h00 HE
|
Y-Prime, LLC
YPrime eCOA research reveals stakeholders' concerns about timelines and data quality.
YPrime Unveils a Transformative Brand Focused on Solving for Certainty in Clinical Trials
22 janv. 2024 07h45 HE
|
Y-Prime, LLC
YPrime announces bold rebranding and re-commitment to provide cutting-edge technologies to streamline and accelerate clinical trials.
OBI-992 獲FDA核准展開一/二期臨床試驗
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
台灣台北電, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技（4174.TWO）今（3）日宣布，旗下以TROP2為標靶、自行研發的抗體藥物複合體（ADC）新藥OBI-992，已獲美國食品藥物管理局（FDA）核准一/二期臨床試驗申請，以評估其安全性及療效。 ...
OBI-992 获FDA核准展开一/二期临床试验
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
台湾台北电, Jan. 03, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技（4174.TWO）今（3）日宣布，旗下以TROP2为标靶、自行研发的抗体药物复合体（ADC）新药OBI-992，已获美国食品药物管理局（FDA）核准一/二期临床试验申请，以评估其安全性及疗效。 ...
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
03 janv. 2024 05h00 HE
|
OBI Pharma Inc.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
02 janv. 2024 08h00 HE
|
Sterling Infosystems, Inc
Sterling to Offer Market Leading Clinical Solutions Through Acquisition of Vault Workforce Screening
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
19 déc. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies,...